Adverse Drug Reactions Associated with Ceftaroline Use: A 2-Center Retrospective Cohort

Blumenthal, Kimberly G.; Kuhlen, James L.; Weil, Ana A.; Varughese, Christy; Kubiak, David W.; Banerji, Aleena; Shenoy, Erica S.

doi:10.1016/j.jaip.2016.03.008

Cited by 31 publications

(33 citation statements)

References 29 publications

(36 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The Naranjo Adverse Drug Reaction Probability Scale was applied as above [19]. Cases in duplicative publications (eg, Blumenthal et al and Furtek et al) were counted once [16, 20]. Cases with preexisting neutropenia before ceftaroline use or cases receiving other agents expected to cause neutropenia (eg, chemotherapy) were excluded, as reported within the respective papers.…”

Section: Methodsmentioning

confidence: 99%

Ceftaroline-Associated Neutropenia: Case Series and Literature Review of Incidence, Risk Factors, and Outcomes

Sullivan

Turner

O’Neal

et al. 2019

Open Forum Infectious Diseases

View full text Add to dashboard Cite

Ceftaroline is increasingly prescribed for “off-label” indications involving longer durations and higher doses. There have been postmarketing case reports of neutropenia among patients who have received extended durations of ceftaroline, but limited published data currently exist on its incidence and risk factors. We review a total of 37 published cases of ceftaroline-associated neutropenia including cases (n = 4) identified in our health care system. The median time from ceftaroline initiation to development of neutropenia (range) was 25 (8–125) days, with a median duration of neutropenia (range) of 4 (1–16) days. Agranulocytosis (absolute neutrophil count [ANC] nadir < 100 cells/mm3) developed in 49% of cases (n = 18), and there was an ANC nadir of 0 in 27% (n = 10). The overall incidence of neutropenia among cases receiving ceftaroline for ≥7–14 days (range) was 12% (7%–18% per individual study), higher than for comparator antibiotics in the literature. Risk factors for ceftaroline-associated neutropenia varied among studies and remain poorly defined.

show abstract

Section: Methodsmentioning

confidence: 99%

Ceftaroline-Associated Neutropenia: Case Series and Literature Review of Incidence, Risk Factors, and Outcomes

Sullivan

Turner

O’Neal

et al. 2019

Open Forum Infectious Diseases

View full text Add to dashboard Cite

show abstract

“…The detection of antibiotic associated ADEs are essential for patient safety. Although numerous studies have been conducted in other countries except Pakistan to determine the preventability associated with ADEs and causal relation of ADRs with antibiotics but those were either limited to a single class of antibiotics or single infection of bacterial origin [ 24 – 27 ]. Therefore, the present study aims to determine the preventability and the reasons of ADEs along with the causal relationship of ADRs with antibiotics that are commonly administered to the hospitalized patients in Pakistan.…”

Section: Introductionmentioning

confidence: 99%

Causality and preventability assessment of adverse drug reactions and adverse drug events of antibiotics among hospitalized patients: A multicenter, cross-sectional study in Lahore, Pakistan

et al. 2018

View full text Add to dashboard Cite

Background and objectivesAdverse drug events (ADEs) are the fifth leading cause of death and thus responsible for a large number of hospital admissions in all over the globe. This study was aimed to assess the antibiotics associated preventability of ADEs and causality of adverse drug reactions (ADRs) among hospitalized patients.MethodsA prospective, cross-sectional, observational study was conducted in four tertiary care public sector hospitals of Lahore, Pakistan. Study population consisted of hospitalized patients who were prescribed with one or more antibiotics. Data were collected between 1st January, 2017 and 31st June, 2017 from 1,249 patients (384 patients aged ≤ 18 years and 865 patients aged >18 years). Schumock and Thornton scale was used to assess the preventability of the ADEs. Medication errors (MEs) that caused preventable ADEs were assessed by MEs tracking form while Naranjo score was used to evaluate the causal relation of ADRs with the antibiotics. Statistical Package for the Social Sciences (IBM SPSS Statistics for Windows, Version 21.0. Armonk, NY: IBM Corp.) and Microsoft Excel (MS Office, 2010) were used for data analysis.Results2,686 antibiotics were prescribed to 1,249 patients. Among them, fluoroquinolones (11.8%), macrolides (11.6%) and cephalosporins (10.9%) were the most frequently prescribed antibiotics. The most affected organ system by antibiotics associated ADEs was gastrointestinal tract. A total of 486 ADEs were found. The preventability assessment revealed that most of the ADEs (58.4%) were preventable (43.6% of the ADEs were definitely preventable while 14.8% were probably preventable) and caused by MEs including wrong drug (40.1%) and monitoring errors (25.0%), during the stage of physician ordering (22.2%) and patient monitoring (21.1%). The errors were caused due to non-adherence of policies (38.4%) and lack of information about antibiotics (32%). Most of the non-preventable ADEs or ADRs among adults and children were “probable” (35.5%) and “possible” (35.8%), respectively. Logistic regression analysis revealed that ADEs were significantly less among females (OR = 0.047, 95%CI = 0.018–0.121, p-value = <0.001), patients aged 18–52 years (OR = 0.041, 95%CI = 0.013–0.130, p-value = <0.001), tuberculosis patients (OR = 0.304, 95%CI = 0.186–0.497, p-value = <0.001), patients with acute respiratory tract infections (OR = 0.004, 95%CI = 0.01−0.019, p-value = <0.001) and among the patients prescribed with 2 antibiotics per prescription (OR = 0.455, 95%CI = 0.319–0.650, p-value = <0.001).ConclusionAccording to preventability assessment most of the ADEs were definitely preventable and caused by MEs due to non-adherence of policies and lack of information about antibiotics. The causality assessment of non-preventable ADEs showed that most of the ADRs were probable and possible.

show abstract

“…She was transferred out of ICU to the step-down unit. The patient continued to tolerate Q8 hour dosing without observed side-effects related to higher doses of ceftaroline fosamil [16]. It is not possible to say if it was a failure of vancomycin or daptomycin.…”

Section: Discussionmentioning

confidence: 99%

Ceftaroline Fosamil as an Alternative for a Severe Methicillin-resistant Staphylococcus aureus Infection: A Case Report

Jilani

Masood

2018

Cureus

View full text Add to dashboard Cite

Bacteremia secondary to methicillin-resistant Staphylococcus aureus (MRSA) is a dreaded medical condition that is not only associated with a significant medical cost but also carries high morbidity and mortality. The poor clinical outcomes seen in MRSA patients and the nephrotoxic effects of high-doses of vancomycin are challenging its current status as the first-line treatment for MRSA. Fortunately, vancomycin-intermediate-staphylococcus aureus (VISA) and vancomycin-resistant-staphylococcus aureus (VRSA) are not common in the United States. However, MRSA still presents different treatment challenges. Elevated vancomycin minimum inhibitory concentrations (MICs) commonly result in decreased efficacy and an increased probability of treatment failure, prompting the use of alternative agents. Although daptomycin is an alternative, adverse effects (i.e., elevations in serum creatine phosphokinase (CPK), drug-induced myopathy, peripheral neuropathy, and eosinophilic pneumonia) may limit its use in some patients. In the search for a suitable replacement for vancomycin, great promise has been shown by anti-MRSA cephalosporins. We present a case of MRSA bacteremia and endocarditis requiring a different approach to treatment as compared to traditional treatment with vancomycin alone. This case report describes the successful treatment of MRSA bacteremia with ceftaroline fosamil in a patient who responded poorly to conventional therapy, specifically vancomycin, due to an elevated MIC (2 µg/mL).

show abstract

Adverse Drug Reactions Associated with Ceftaroline Use: A 2-Center Retrospective Cohort

Cited by 31 publications

References 29 publications

Ceftaroline-Associated Neutropenia: Case Series and Literature Review of Incidence, Risk Factors, and Outcomes

Ceftaroline-Associated Neutropenia: Case Series and Literature Review of Incidence, Risk Factors, and Outcomes

Causality and preventability assessment of adverse drug reactions and adverse drug events of antibiotics among hospitalized patients: A multicenter, cross-sectional study in Lahore, Pakistan

Ceftaroline Fosamil as an Alternative for a Severe Methicillin-resistant Staphylococcus aureus Infection: A Case Report

Contact Info

Product

Resources

About